These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Report from the 13th retrovirus conference. New data on TMC114 and TMC125. Hicks CB AIDS Clin Care; 2006 Apr; 18(4):34. PubMed ID: 16718876 [No Abstract] [Full Text] [Related]
4. Drug interactions. Amprenavir with low-dose ritonavir. TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921 [No Abstract] [Full Text] [Related]
5. 13th annual HIV drug guide. Djuricich P; Vázquez E Posit Aware; 2009; 20(2):28-55. PubMed ID: 19280745 [No Abstract] [Full Text] [Related]
6. 12th annual HIV drug guide. Diaz-Linares M; Vázquez E; Gallant J; Delaney M Posit Aware; 2008; 19(1):19-48. PubMed ID: 18546577 [No Abstract] [Full Text] [Related]
7. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r]. MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981 [No Abstract] [Full Text] [Related]
8. Etravirine(Intelence) for HIV infection. Med Lett Drugs Ther; 2008 Jun; 50(1288):47-8. PubMed ID: 18551091 [No Abstract] [Full Text] [Related]
9. New treatment options. Fornataro K; Jefferys R Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013 [TBL] [Abstract][Full Text] [Related]
10. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860 [TBL] [Abstract][Full Text] [Related]
11. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV. Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091 [TBL] [Abstract][Full Text] [Related]
12. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421 [TBL] [Abstract][Full Text] [Related]
13. New protease inhibitor. Vazquez E Posit Aware; 1999; 10(3):24. PubMed ID: 11366764 [TBL] [Abstract][Full Text] [Related]
14. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
15. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B; HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960 [TBL] [Abstract][Full Text] [Related]